IL-33 and HMGB1 modulate the progression of EAE via oppositely regulating each other

Int Immunopharmacol. 2023 Sep:122:110653. doi: 10.1016/j.intimp.2023.110653. Epub 2023 Jul 18.

Abstract

Interleukin-33 (IL-33) and high mobility group box 1 (HMGB1) have been reported to play crucial and distinct roles in experimental autoimmune encephalomyelitis (EAE). However, little is known about their interaction in the progression of EAE. In this study, the dynamic expression and release of IL-33 and HMGB1 in different stages of EAE in vivo, and their interaction in vitro were explored. We found that HMGB1 was dominant in pre-onset stage of EAE, while IL-33 was dominant in peak stage. Moreover, both blockade of extracellular HMGB1 in the central nervous system (CNS) and conditional knockout of HMGB1 in astrocytes decreased IL-33 release. HMGB1 promoted the release of IL-33, while IL-33 reduced the release of HMGB1 from primary astrocytes in vitro. Taken together, IL-33 and HMGB1 in the CNS jointly participate in the EAE progression and the inhibitory effect of IL-33 on HMGB1 may be involved in the self-limiting of EAE.

Keywords: Astrocytes; EAE; HMGB1; IL-33.

MeSH terms

  • Animals
  • Astrocytes
  • Central Nervous System
  • Encephalomyelitis, Autoimmune, Experimental*
  • HMGB1 Protein* / metabolism
  • Interleukin-33 / metabolism
  • Mice
  • Mice, Inbred C57BL

Substances

  • Interleukin-33
  • HMGB1 Protein